Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andrew Barksdale

Thoracic Surgery (Cardiothoracic Vascular Surgery) Indianapolis, IN Medical Doctor

NPI 1538363247 CMS profile 69389

5255 East Stop 11 Rd., #200, Indianapolis, IN 46237

Open in the dashboard

General payments

$158,012

406 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andrew Barksdale of Indianapolis, IN is reported in the CMS Open Payments database as having received $158,012 across 406 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,112 49
2024 General $1,079 32
2023 General $1,118 29
2022 General $913 20
2021 General $35,585 53
2020 General $37,240 77
2019 General $79,966 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andrew Barksdale
  • Thoracic Surgery (Cardiothoracic Vascular Surgery) median
  • Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
  • National median

In program year 2025, general payments to Andrew Barksdale were reported at $2,112. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.

Show as a table
Year Andrew Barksdale Thoracic Surgery (Cardiothoracic Vascular Surgery) median Middle half National median
2019 $79,966 $886 $178–$3,167 $163
2020 $37,240 $341 $108–$1,605 $114
2021 $35,585 $453 $125–$1,886 $132
2022 $913 $695 $180–$2,566 $149
2023 $1,118 $745 $205–$2,662 $160
2024 $1,079 $799 $214–$2,967 $164
2025 $2,112 $791 $208–$3,074 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $140,497 228 payments
  2. Edwards Lifesciences Corporation $9,844 25 payments
  3. ClearFlow, Inc. $1,702 2 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $990 50 payments
  5. Abiomed $946 13 payments
  6. CryoLife, Inc. $780 5 payments
  7. Zimmer Biomet Holdings, Inc. $562 13 payments
  8. Bolton Medical Inc $553 4 payments
  9. AngioDynamics, Inc. $266 6 payments
  10. Abbott Laboratories $236 9 payments
  11. Other $1,635 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $124,500 50 payments
  2. Travel and Lodging $23,157 115 payments
  3. Food and Beverage $10,355 241 payments
Products named General payments · program years 2019–2025
  1. EPI-SENSE GUIDED COAGULATION SYS $36,664 60 payments
  2. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $26,185 34 payments
  3. ATRICLIP LAA EXCLUSION SYSTEM $17,487 27 payments
  4. PleuraFlow $1,680 1 payment
  5. LifeVest $990 50 payments
  6. Impella $790 11 payments
  7. ATRICURE SYNERGY ABLATION SYSTEM $790 7 payments
  8. AMDS-Ascyrus Medical $717 3 payments
  9. SYNERGY ABLATION SYSTEM $424 10 payments
  10. ATRICURE ATRICLIP LAA EXCLUSION $361 4 payments
  11. Other $4,314 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

50

Median for Thoracic Surgery: 42

Drug cost

$303

Median for Thoracic Surgery: $318

Branded share of claims

30%

Median for Thoracic Surgery: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 15 $153
Metoprolol Succinate Generic 15 $91
Atorvastatin Calcium Generic 20 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 910 Part D prescribers listed as Thoracic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$95,819

Medicare's payments for the services billed

Medicare patients

92

Average age 72

Services billed

303

29 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 54%
Atrial fibrillation 54%
Arthritis 52%
Chronic kidney disease 49%
COPD 49%
Diabetes 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

406 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record